Cocrystal Pharma, Inc. (NASDAQ:COCP) Short Interest Up 563.7% in April
by Jessica Moore · The Cerbat GemCocrystal Pharma, Inc. (NASDAQ:COCP – Get Free Report) was the recipient of a large growth in short interest in the month of April. As of April 15th, there was short interest totaling 988,346 shares, a growth of 563.7% from the March 31st total of 148,911 shares. Based on an average daily volume of 14,037,342 shares, the short-interest ratio is currently 0.1 days. Approximately 10.0% of the shares of the company are sold short.
Cocrystal Pharma Price Performance
Shares of NASDAQ:COCP traded up $0.02 during trading on Friday, hitting $1.43. The company’s stock had a trading volume of 133,739 shares, compared to its average volume of 7,389,464. The company has a 50-day moving average of $1.18 and a 200-day moving average of $1.09. Cocrystal Pharma has a 12 month low of $0.86 and a 12 month high of $2.67. The firm has a market cap of $19.72 million, a price-to-earnings ratio of -1.81 and a beta of 1.18.
Cocrystal Pharma (NASDAQ:COCP – Get Free Report) last issued its quarterly earnings data on Tuesday, March 31st. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.01. As a group, research analysts anticipate that Cocrystal Pharma will post -0.67 earnings per share for the current year.
Insider Buying and Selling at Cocrystal Pharma
In other Cocrystal Pharma news, Director Phillip Md Et Al Frost acquired 50,000 shares of the stock in a transaction dated Friday, February 6th. The shares were purchased at an average price of $0.95 per share, for a total transaction of $47,500.00. Following the purchase, the director directly owned 1,888,551 shares of the company’s stock, valued at approximately $1,794,123.45. This trade represents a 2.72% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 28.14% of the stock is owned by company insiders.
Hedge Funds Weigh In On Cocrystal Pharma
An institutional investor recently bought a new position in Cocrystal Pharma stock. T3 Companies LLC acquired a new position in Cocrystal Pharma, Inc. (NASDAQ:COCP – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 52,300 shares of the company’s stock, valued at approximately $51,000. T3 Companies LLC owned 0.38% of Cocrystal Pharma as of its most recent SEC filing. Institutional investors own 6.72% of the company’s stock.
Cocrystal Pharma Company Profile
Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.
The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.